Sort   by:  
 Page size 
ProteomicsIn-cell isotope-coded labeling and LC-MS/MS analysis probe warfarin inhibition mechanism
Warfarin targets human vitamin K epoxide reductase (hVKOR), a redox enzyme in the membrane of endoplasmic reticulum (ER), to prevent the formation of blood clots. Although warfarin has been a popular medication since 1954, its mechanism of action is still unclear. A fundamental issue is the controve...
ORGANISM(S): Homo sapiens (Human) 
2017-03-30 | PXD003774 | Pride
Human vitamin k epoxide reuctase N-ethylmeleimide Isotope Bottom-up proteomics Warfarin 
GenomicsGenome-wide association study of response to warfarin in a UK prospective cohort
Genome-wide association study of Warfarin dosing in 714 British, recruited in Liverpool and Birmingham. Three phenotypes were investigated: warfarin mean dose, warfarin mean stable dose, and INR over 4 during first week of treatment. Stability was defined by at least three INR measurements within ta...
EGAS00001001130 | EGA
UnknownEstimation of the warfarin dose with clinical and pharmacogenetic data.
Not available
S-EPMC2722908 | biostudies-literature
GenomicA Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics

Warfarin is an oral anticoagulant and one of the most used drugs in the world accounting for up to 1.5% of prescriptions globally. Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1), an enzyme responsible for the vitamin K recycling that is required for the activation of clotting fa...

phs001496 | dbGaP
GenomicsA Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
PRJNA421230 | ENA
GenomicsA Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics
PRJNA421231 | ENA
GenomicsUK Warfarin Consortium
Data Access Committee EGAC00001000301
EGAC00001000301 | EGA
GenomicsPharmacogenetic Optimization of Anticoagulant Response (POAT) and Genetic and Environmental Determinants of Warfarin Response (GEDWR)
Pharmacogenetic Optimization of Anticoagulant Response (POAT) and Genetic and Environmental Determinants of Warfarin Response (GEDWR)
PRJNA236403 | ENA
UnknownPrevalence and factors associated with psychological distress among patients on warfarin at the Uganda Heart Institute, Mulago Hospital.
Not available
S-EPMC9123720 | biostudies-literature
GenomicWarfarin Pharmacogenetics: Pharmacogenetic Optimization of Anticoagulant Response (POAT) and Genetic and Environmental Determinants of Warfarin Response (GEDWR)

Although the efficacy of warfarin in the treatment and prevention of thromboembolic disorders is proven, it is vastly underutilized with difficulties in management and risk of complications being the main deterrents. Recognition of genetic regulation of warfarin response has fueled efforts to qua...

phs000708 | dbGaP
Sort   by:  
 Page size